MD Anderson Researchers Advance Cancer Treatment with Novel Pan-KRAS Inhibitor and Precision Therapies
Key Insights
MD Anderson researchers developed BI-2493, a first-in-class pan-KRAS (search) inhibitor that targets multiple KRAS mutations across cancer types, showing strong antitumor activity in pancreatic cancer (search) models.
The ELI-002 2P immunotherapy vaccine demonstrated promising results in KRAS (search)-mutated pancreatic and colorectal cancers, with 68% of patients showing robust T cell responses and 75% remaining relapse-free at highest dose levels.
Multiple breakthrough studies revealed new treatment strategies including targeted radiation for kidney cancer, triple combination therapy for BRAF-mutant colorectal cancer (search), and novel biomarkers for predicting oral cancer (search) metastasis.
Researchers at The University of Texas MD Anderson Cancer Center have unveiled multiple breakthrough developments in cancer treatment, with particular emphasis on targeting previously difficult-to-treat mutations and improving precision therapy approaches across various cancer types.
Pan-KRAS Inhibitor Shows Promise Across Multiple Cancer Types
A collaborative effort between MD Anderson and Boehringer Ingelberg has produced BI-2493, a first-in-class pan-KRAS (search) inhibitor capable of targeting mutant KRAS proteins regardless of specific mutation type. Led by researchers Kathleen McAndrews, Ph.D., Anirban Maitra, M.B.B.S., Raghu Kalluri, M.D., Ph.D., and Timothy Heffernan, Ph.D., the study addresses a critical challenge in oncology, as KRAS represents the most commonly mutated gene in cancer yet has proven notoriously difficult to target therapeutically.
In preclinical pancreatic cancer (search) models, BI-2493 effectively suppressed tumor growth in vitro and prolonged survival in vivo, with confirmed RAS pathway inhibition. Beyond direct antitumor effects, the inhibitor demonstrated significant tumor microenvironment remodeling capabilities, increasing intratumoral immune cells while decreasing myeloid cells, thereby enhancing immunotherapy response potential.
KRAS-Targeted Vaccine Delivers Sustained Clinical Benefits
The AMPLIFY-201 trial, co-led by Shubham Pant, M.D., has provided compelling long-term data for the ELI-002 2P immunotherapy vaccine targeting lymph nodes in patients with KRAS (search)-mutated pancreatic and colorectal cancers. Final follow-up results showed that 17 of 25 patients (68%) developed robust T cell responses, which correlated with increased survival outcomes.
At 24 months, patients in the higher response group—including all patients at the highest two dose levels—had not yet reached median recurrence-free survival, with 75% remaining relapse-free compared to just three months for non-responders. These promising results have prompted initiation of a Phase II trial featuring an enhanced formulation, ELI-002 7P, designed to target additional KRAS (search) mutations.
Precision Radiation Therapy Delays Systemic Treatment in Kidney Cancer
A Phase II clinical trial led by Chad Tang, M.D., and Pavlos Msaouel, M.D., Ph.D., demonstrated that metastasis-directed targeted radiation therapy can effectively delay systemic treatment in patients with oligometastatic clear cell renal cell carcinoma (search) (ccRCC). Among 121 patients, survival rates remained high with 94% alive at two years and 87% at three years, while patients achieved a median of 34 months without requiring systemic treatment.
The study incorporated a novel circulating tumor DNA (ctDNA) test that revealed patients with no detectable disease stayed off systemic treatments twice as long as those with detectable traces, suggesting this biomarker could guide future patient selection for this treatment approach.
Triple Combination Targets Treatment-Resistant Colorectal Cancer
Van Morris, M.D., and colleagues addressed the challenge of microsatellite stable (MSS) BRAF V600E (search)-mutant metastatic colorectal cancer (search) by adding the anti-PD-1 (search) antibody nivolumab to the FDA-approved combination of encorafenib and cetuximab. This Phase I/II trial of 26 patients achieved a 50% overall response rate with median progression-free survival exceeding seven months.
RNA analysis from liquid biopsies identified distinct response patterns among patients, providing insights into treatment optimization. The positive outcomes led to the launch of SWOG S2107, a nationwide Phase II trial in the same patient population.
Advanced Technologies Enable Precision Cancer Research
MD Anderson researchers have developed several innovative technologies to advance cancer understanding and treatment. Nicholas Navin, Ph.D., created wellDR-seq, a single-cell DNA and RNA sequencing technology that profiled 33,646 single cells from 12 estrogen-receptor-positive breast cancers, revealing molecular insights into cancer progression and invasion patterns.
Yuan-Hung Lo, Ph.D., utilized CRISPR gene editing tools in stomach organoids to identify unexpected connections between cisplatin sensitivity and fucosylation processes, discovering the TAF6L (search) gene as a key regulator of cell recovery from cisplatin-induced cytotoxicity.
Biomarker Discovery Advances Oral Cancer Management
Koichi Takahashi, M.D., Ph.D., and Ken Furudate, D.M.D., Ph.D., conducted comprehensive spatial analysis of oral cancer (search) tumor microenvironments, identifying increased levels of myofibroblastic cancer-associated fibroblasts (myCAFs) within invasive tumor fronts. Their research produced a 23-gene signature capable of predicting lymph node metastasis and poor prognosis in oral cancer patients.
High-Dose Chemotherapy Improves Outcomes in Refractory Testicular Cancer
Yago Nieto, M.D., Ph.D., led a Phase II trial examining high-dose chemotherapy targeting DNA damage repair pathways combined with bevacizumab in 65 patients with multiply relapsed and heavily pretreated germ-cell tumors. The study achieved five-year relapse-free and overall survival rates of 54% and 55.5%, respectively, exceeding expectations. While bevacizumab addition did not improve outcomes, the results were validated in a prospective cohort of 100 patients with similar poor prognosis.
These research advances represent significant progress in precision oncology, offering new therapeutic options for previously difficult-to-treat cancers while advancing understanding of tumor biology and treatment resistance mechanisms.